Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20503341 | 0.90 | LMNA (0.60) | LMNAHSD11B1L3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL156165 | 0.87 | HSD11B1 (0.55) | LMNAHSD11B1L3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL111775 | 0.85 | HSD11B1 (0.53) | LMNAHSD11B1L3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL28624762 | 0.84 | KMT2A (0.49) | LMNANPSR1CA12CA1CA2 | |
| SCHEMBL28621564 | 0.84 | GAA (0.47) | LMNASMN1; SMN2MAPTCYP2D6PKM | |
| SCHEMBL7523793 | 0.84 | HSD11B1 (0.51) | LMNAHSD11B1L3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL8664448 | 0.83 | KMT2A (0.47) | LMNAHSD11B1CA2 | |
| SCHEMBL8662612 | 0.83 | NPC1 (0.57) | HSD11B1KDM4E | |
| SCHEMBL114044 | 0.83 | ALDH1A1 (0.57) | LMNAMAPTCA12CA1CA2 | |
| SCHEMBL9096645 | 0.83 | HSD11B1 (0.47) | LMNAHSD11B1L3MBTL1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2024-06-20 | — | — | US | claimed |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2024-01-09 | — | — | US | claimed |
| US-8568960-B2 | Multiple exposure photolithography methods | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2013-10-29 | — | — | US | claimed |
| US-20120178027-A1 | MULTIPLE EXPOSURE PHOTOLITHOGRAPHY METHODS | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2012-07-12 | — | — | US | claimed |
| EP-2240828-A1 | MULTIPLE EXPOSURE PHOTOLITHOGRAPHY METHODS AND PHOTORESIST COMPOSITIONS | International Business Machines Corporation (US) | 2010-10-20 | — | — | EP | claimed |
| WO-2009087029-A1 | MULTIPLE EXPOSURE PHOTOLITHOGRAPHY METHODS AND PHOTORESIST COMPOSITIONS | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2009-07-16 | — | — | WO | claimed |
| US-20090176174-A1 | MULTIPLE EXPOSURE PHOTOLITHOGRAPHY METHODS AND PHOTORESIST COMPOSTIONS | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2009-07-09 | — | — | US | claimed |
| US-20260124214-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2026-05-07 | — | — | US | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| CN-118234728-A | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | disclosed |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| US-5527805-A | DNA-CLEAVING, CYTOTOXIC AND ANTI-TUMOR COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-06-18 | — | — | US | disclosed |
| US-5384412-A | 4-trihydrocarbylsiloxy-6-methyltetrahydropyran derivatives; anticarcinogenic agents | THE SCRIPPS RESEARCH INSTITUTE (US) | 1995-01-24 | — | — | US | disclosed |
| EP-0594624-A1 | DYNEMICIN ANALOGS: SYNTHESES, METHODS OF PREPARATION AND USE | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1994-05-04 | — | — | EP | disclosed |
| EP-0594624-A4 | DYNEMICIN ANALOGS: SYNTHESES, METHODS OF PREPARATION AND USE. | SCRIPPS CLINIC RES (US) | 1994-02-21 | — | — | EP | disclosed |
| US-5281710-A | Antibiotics or antitumor agents | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-01-25 | — | — | US | disclosed |
| US-5276159-A | Antitumor | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-01-04 | — | — | US | disclosed |
| WO-1992002522-A1 | DYNEMICIN ANALOGS: SYNTHESES, METHODS OF PREPARATION AND USE | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1992-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | LMNA 816/4885HSD11B1 1529/4885L3MBTL1 914/4885 |
| US-20260124214-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CBR1, NR3C1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | LMNA 597/4885HSD11B1 43/4885L3MBTL1 2221/4885 |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | LMNA 646/4885HSD11B1 960/4885L3MBTL1 1230/4885 |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | LMNA 646/4885HSD11B1 960/4885L3MBTL1 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.